These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1481 related items for PubMed ID: 17713864

  • 21. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A.
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [Abstract] [Full Text] [Related]

  • 22. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P.
    J Clin Oncol; 2004 Jul 15; 22(14):2835-41. PubMed ID: 15199092
    [Abstract] [Full Text] [Related]

  • 23. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
    Kirchner EM, Ebsen M, Kirchner J, Theegarten D, Voigtmann R.
    Ann Oncol; 2001 Aug 15; 12(8):1169-71. PubMed ID: 11583202
    [Abstract] [Full Text] [Related]

  • 24. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M, Giannouli S, Anagnostou D, Tzioufas AG.
    Rheumatology (Oxford); 2004 Aug 15; 43(8):1050-3. PubMed ID: 15187246
    [Abstract] [Full Text] [Related]

  • 25. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N, Ishibashi K, Uno H, Hino N.
    Gan To Kagaku Ryoho; 2002 Dec 15; 29(13):2569-72. PubMed ID: 12506485
    [Abstract] [Full Text] [Related]

  • 26. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S, Dührsen U, Nückel H.
    Ann Hematol; 2007 Apr 15; 86(4):271-6. PubMed ID: 17216473
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM.
    Ann Hematol; 2007 Feb 15; 86(2):101-5. PubMed ID: 17089127
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone].
    Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V.
    Dtsch Med Wochenschr; 1983 Sep 23; 108(38):1428-32. PubMed ID: 6192987
    [Abstract] [Full Text] [Related]

  • 32. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
    Koza I, Bohunický L, Mociková K, Gyárfás J, Svancárová L, Mardiak J, Spánik S, Fuchsberger P, Thalmeinerová Z, Sufliarsky J.
    Neoplasma; 1991 Sep 23; 38(6):583-93. PubMed ID: 1722564
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Greater curability in advanced Hodgkin's disease?
    Portlock CS.
    Cancer J Sci Am; 1999 Sep 23; 5(5):264-5. PubMed ID: 10526665
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group.
    Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R.
    J Clin Oncol; 1994 Mar 23; 12(3):580-6. PubMed ID: 8120557
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Third-line salvage chemotherapy in Hodgkin's disease.
    Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A.
    Semin Oncol; 1985 Mar 23; 12(1 Suppl 2):23-5. PubMed ID: 2579440
    [Abstract] [Full Text] [Related]

  • 40. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K, Utsumi M, Shimoyama M.
    Gan To Kagaku Ryoho; 1998 Dec 23; 25(14):2202-9. PubMed ID: 9881076
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 75.